Journal article
Development of Cell-Based Tuberculosis Vaccines: Genetically Modified Dendritic Cell Vaccine Is a Much More Potent Activator of CD4 and CD8 T Cells Than Peptide- or Protein-Loaded Counterparts
Abstract
Genetically modified dendritic cell (DC)-based vaccines have not been explored for immunization against tuberculosis. A gene-modified DC vaccine expressing Mycobacterium tuberculosis (M.tb) antigen 85A (Ag85A) was developed by using a recombinant replication-deficient adenoviral gene transfer vector (AdAg85A). AdAg85A-transduced DC vaccine (AdAg85/DC) expressed higher levels of IL-12 and was much more immunogenic than Ag85 protein-loaded …
Authors
Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y
Journal
Molecular Therapy, Vol. 13, No. 4, pp. 766–775
Publisher
Elsevier
Publication Date
April 2006
DOI
10.1016/j.ymthe.2005.10.018
ISSN
1525-0016
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdenoviridaeAnimalsBone Marrow CellsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedCytotoxicity Tests, ImmunologicDendritic CellsFemaleFlow CytometryInjections, IntramuscularInjections, IntravenousInterferon-gammaMiceMice, Inbred BALB CMycobacterium tuberculosisSpleenTime FactorsTransduction, GeneticTuberculosis VaccinesVaccines, Synthetic